drugset / Trial / NCT00993863

Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction

NCT00993863

Phase 2 Completed 201 enrolled Merck & Co., Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of this study is to evaluate the analgesic efficacy and safety of ADL5859 compared with placebo and an active control (ibuprofen) in subjects with acute dental pain after third molar extraction.

Timeline

Start
2007-06
Primary completion
2007-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject ADL5859 Small molecule 30 mg
Subject ADL5859 Small molecule 100 mg
Subject ADL5859 Small molecule 200 mg
Comparator Ibuprofen Small molecule 400 mg

Indications

No indication recorded.